Skip to content

Ascendis Pharma A/S

ASND

CIK 0001612042 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
€530.47M
+98.0% YoY FY Dec 2025
Net Income (TTM)
−€293.67M
+39.7% YoY FY Dec 2025
EPS Diluted (TTM)
−€7.51
+42.4% YoY FY Dec 2025
Gross Margin
84.4%
FY Dec 2025
Operating Margin
-45.8%
FY Dec 2025
Net Margin
-55.4%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
€616.04M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
61.98M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings